Patients benefit from treatments tailored specifically for their tumor types; stage set for larger studyContinue reading
Category Archives: AZBio News
12th Annual BIO Investor Forum in October
Announcing the 12th Annual BIO Investor Forum
The Biotechnology Industry Organization (BIO) is pleased to announce its advisory committee for the 12th Annual BIO Investor Forum, an international biotech investor conference focused on investment strategies for early stage and established private companies as well as emerging public companies. The event will take place October 8-9, 2013 at the Palace Hotel in San Francisco, Calif.
This esteemed group will help set the agenda and program for this year’s event which will assemble public and venture-stage growth companies, as well as top public and private equity investors, to explore investment trends and opportunities in life sciences.
Advisory Committee members include:
- Srini Akkaraju, MD, PhD, General Partner, Sofinnova Venture
- Katrine Bosley, (former) CEO, Avila Therapeutics
- Ashley Dombkowski, CBO, 23andMe
- Todd Foley, Managing Director, MPM Capital
- Gail Maderis, President & CEO, BayBio
- Janis Naeve, PhD, Managing Director, Amgen Ventures
- Bryan Roberts, PhD, Partner, Venrock
- Eugene Rozelman, Managing Director, Canaccord Genuity
- Francesco De Rubertis, PhD, Partner, Index Ventures
- Geeta Vemuri, PhD, VP, Head, Baxter Ventures
- Barbara Yanni, Vice President & Chief Licensing Officer, Merck
- Krishna Yeshwant, Partner, Google Ventures
In addition to panel discussions led by clinical thought leaders focusing on hot therapeutic areas, the conference features business roundtables focused on financing, investment and the latest M&A trends. BIO One-on-One Partnering™ will also provide an opportunity to arrange meetings between investors; companies; and industry business development, licensing and therapeutic franchise heads.
The BIO Investor Forum has become the ideal venue for investors and business development leaders to discuss financial and strategic business issues affecting investment in biotech companies, and explore potential partnerships and business collaborations to fuel research and development for promising innovation. Last year’s conference scheduled over 650 meetings. Nearly 80% of all requests were between biotech companies and investors. Furthermore, the event hosted nearly 110 late-stage private and emerging public company presentations.
The meeting attracts healthcare venture capital and public market investors and research analysts as well as business development executives from leading global pharmaceutical and biotechnology companies.
For more information, please go to bio.org/investorforum.
BIO Investor Forum Features
- BIO 1×1 Meetings
- Plenary Sessions and Workshops
- Company Presentations
- Networking Opportunities
Venue Information
2 New Montgomery Street
San Francisco, CA 94105
What will the BIO Investor Forum mean to your company?Contact Us
Customer Service:
1.866.356.5155 (U.S.) or
+1.202.962.6666 (International)
biopartnering@bio.org.
Sponsorship Opportunities:
John Sloan, Managing Director,
External Relations & Development, BIO
jsloan@bio.org.
MEDICAL TECHNOLOGY MANUFACTURERS SURPASS $1 BILLION PAYMENT TO IRS FOR DEVICE TAX
Washington, D.C. – The Medical Imaging & Technology Alliance (MITA), the Advanced Medical Technology Association (AdvaMed) and the Medical Device Manufacturers Association (MDMA) today announced that medical device manufacturers have now paid an estimated $1 billion to the Internal Revenue Service for the medical device excise tax. In reaching this threshold, the device tax has denied device manufacturers the resources that would have otherwise been available to invest in research and development (R&D), capital investments and to support good-paying jobs across America.Continue reading
BioPharm Insight Analysis: Ulthera
Ulthera evaluating exit strategies in wake of turning cash-flow positive – CEO BioPharm InsightContinue reading
Iron Horse Diagnostics partnership for ALS diagnostics on the horizon
Iron Horse Diagnostics partnership for ALS diagnostics on the horizon, raising USD 4m for TBI program
- Two 250-patient TBI trials planned for when funding is in place
- ALS diagnostics validation process to be complete in four months
- Seeking CRO for ALS, and eventually TBI, diagnostics trialsContinue reading
MSDx Welcomes David McCaleb to its Board of Directors
MSDx, Inc., announced today that David McCaleb has joined its Board of Directors. With over thirty years of experience in leading pharmaceutical companies and biotech start-ups, his successful track record in commercialization and fundraising will augment the MSDx team. Continue reading
U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease
In a big step forward for Alzheimer’s disease (AD) therapy development, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have independently reached favorable decisions on the value of Critical Path Institute’s new disease simulation tool for improving trial design in mild and moderate Alzheimer’s disease. The first such instrument to ever receive this regulatory designation, the tool represents an enabling advance to improve the design of future clinical trials in AD. The new tool applies computerized models to simulate “what-if” scenarios for clinical trials.
The goal of this virtual tool is to serve as a public resource for sponsors designing trials of new therapies for AD.Continue reading
Biodesign Researchers Track The Global Spread of Malaria
Malaria in the Americas presents a complex pictureContinue reading
FDA Names UA Antivenom Expert Hero of Rare Diseases
For her groundbreaking work on developing treatments for snakebites and scorpion stings, UA physician-scientist Leslie Boyer has been named a Hero of Rare Diseases by the FDA.Continue reading
Calimmune Initiates HIV Stem Cell Study at Two California Research Sites
The HIV gene medicines company, Calimmune, announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, “Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection,” utilizes a gene medicine called Cal-1, developed in the lab of Nobel Laureate Dr. David Baltimore and by Calimmune.Continue reading